Sign inJoin waitlistJoin the waitlist

Vadim Koshkin

Assoc Professor Clinical Med · University of California (San Francisco) School of Medicine

Credentials: · · · · · ·

History

Hematology and Medical Oncology
Cleveland Clinic
2015–2018
Internal Medicine
University of Michigan
2012–2015
University of Chicago Division of the Biological Sciences, The Pritzker School of Medicine
2008–2012
University of Pennsylvania
2004–2007

Research

Association of clinical factors and recent anticancer therapy with COVID-19 severity among patients with cancer: a report from the COVID-19 and Cancer Consortium
Annals of Oncology · 2021 · 260 citations
Association of Convalescent Plasma Therapy With Survival in Patients With Hematologic Cancers and COVID-19
JAMA Oncology · 2021 · 161 citations
Clinical activity of nivolumab in patients with non-clear cell renal cell carcinoma
Journal for ImmunoTherapy of Cancer · 2018 · First of 15 authors · 160 citations

Petros Grivas
40 papers
Mehmet Bilen
34 papers
Rana McKay
31 papers · 9 as a resident
AA
Ajjai Alva
25 papers
Ali Khaki
22 papers
Shilpa Gupta
22 papers
Terence Friedlander
21 papers
Yousef Zakharia
20 papers
Clara Hwang
19 papers
Deepak Kilari
18 papers
Abhishek Tripathi
17 papers
Daniel Kwon
17 papers · 7 as a fellow

Clinical trials

N-803 in Combination With Pembrolizumab and Enfortumab Vedotin for Treatment of Urothelial Cancer
Principal investigator · Withdrawn · Phase 1
Vadim S Koshkin
2026–2027
Enfortumab Vedotin and Pembrolizumab Combined With Radiotherapy in Muscle Invasive Bladder Cancer
Principal investigator · Recruiting · Phase 1, Phase 2
University of California, San Francisco
2025–2028
Abemaciclib Before 177Lu-PSMA-617 for the Treatment of Metastatic Castrate Resistant Prostate Cancer
Principal investigator · Recruiting · Phase 1, Phase 2
Vadim S Koshkin
2022–2028
A Study of Vepugratinib (LY3866288) in Participants With Cancer in the Urinary Tract
Site PI · Recruiting · Phase 3
Eli Lilly and Company
2025–2033